Preclinical Research Findings of Dor Bio's Trispecific Antibody DR30206 Published in International Immunopharmacology

On February 21, 2024, Zhejiang Doer Biologics Co., Ltd. published the preclinical research results of its self-developed trispecific antibody DR30206 in the highly influential journal "International Immunopharmacology" in the fields of immunology and pharmacology.

The immunosuppression of the tumor microenvironment is inseparable from tumor progression. Programmed death ligand/receptor (PD-L1/PD-1), vascular endothelial growth factor (VEGF), and transforming growth factor β (TGF-β) are jointly involved in the regulation of the tumor microenvironment (TME). Monotherapy with immune checkpoint inhibitors (ICIs, such as PD-1/PD-L1 antibodies) can easily lead to immune escape, while combination therapies often result in high toxicity and side effects.

The design concept of the trispecific antibody fusion protein DR30206 is to enhance immune response by targeting PD-L1 while inhibiting VEGF and TGF-β in the TME, based on a single-molecule antibody, with the aim of effectively suppressing tumor growth.

Image Source: Doer Biologics WeChat Official Account

The structural design of DR30206 is first based on Doer Biologics' independently developed SMART-VHHBody platform technology, through which a single-domain antibody sequence specifically targeting PD-L1 was screened and obtained. The anti-PD-L1 single-domain antibody and the TGF-β receptor were fused to the N-terminus and C-terminus of the VEGF antibody Bevacizumab, respectively, forming a tri-specific antibody fusion protein structure.

DR30206 exhibits high affinity and blocking activity against VEGF, TGFβ, and PD-L1 targets. It has demonstrated superior anti-tumor activity and favorable non-clinical safety in multiple immune-reconstructed tumor-bearing mouse models, indicating significant potential value for clinical development. DR30206 has now entered Phase I clinical trials.

Editor: Liuli

Disclaimer: This article is a reprint from PharmNet. The images and text are the property of the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.